2 Brain/Neuro Cancer 2 1 0 30 34 101 http://clinicaltrials.dfhcc.harvard.edu/trials/101 Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor RATIONALE: Octreotide and interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving octreotide together with interferon alfa-2b is more effective than giving octreotide together with bevacizumab in treating patients with neuroendocrine tumor. PURPOSE: This randomized phase III trial is studying giving octreotide together with interferon alfa-2b to see how well it works compared with giving octreotide together with bevacizumab in treating patients with metastatic or locally advanced, high-risk neuroendocrine tumor. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 3 1 http://clinicaltrials.dfhcc.harvard.edu/trials/1 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma The purpose of this study is to find out what effects, good and/or bad, sunitinib has on patients and their tumors. At this time, no drugs are routinely used to treat meningioma, hemangioblastoma or hemangiopericytoma. Only surgery and radiation therapy are known to be useful. Sunitinib is a drug approved for advanced kidney cancer. Sunitinib is also being studied for other tumors. It may be useful in the treatment of brain tumors because it can prevent formation of new blood vessels that allow tumor cells to survive and grow. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 2 26 http://clinicaltrials.dfhcc.harvard.edu/trials/26 A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas The purpose of this research study is to determine if armodafinil is safe and effective in treating fatigue in patients with malignant gliomas undergoing treatment with radiotherapy plus temodar. Armodafinil is a wakefulness-promoting agent that has been FDA approved for the treatment of excessive daytime sleepiness for a variety of disorders. Armodafinil may also help to reduce radiation-induced fatigue in brain tumor patients. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 2 81 http://clinicaltrials.dfhcc.harvard.edu/trials/81 Monthly SOM230C for Recurrent or Progressive Meningioma The purpose of this research study is to evaluate the effectiveness and safety of SOM230C in treating recurrent meningiomas. SOM230C is a newly discovered drug that may stop meningioma cells from growing abnormally. This drug has been used in treatment of other tumors, and information from those other research studies suggests that SOM230C may help to stop the growth of meningiomas. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 2 107 http://clinicaltrials.dfhcc.harvard.edu/trials/107 Dose-Intense Temozolomide in Recurrent Glioblastoma Temozolomide (Temodar) is an FDA approved medication for the treatment of newly diagnosed glioblastomas. In this study, we will be using temozolomide to treat recurrent glioblastomas. We will be using a different dose and schedule than the FDA approved dose and schedule. The purpose of this study is to determine if patients that have failed standard temozolomide treatment will respond to temozolomide when given at a different dose and schedule (21 days every 28 days). Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 2 142 http://clinicaltrials.dfhcc.harvard.edu/trials/142 Pazopanib in Treating Patients With Advanced Neuroendocrine Cancer RATIONALE: Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well pazopanib works in treating patients with advanced neuroendocrine cancer. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 2 301 http://clinicaltrials.dfhcc.harvard.edu/trials/301 Study of XL184 in Adults With Glioblastoma Multiforme The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 2 903 http://clinicaltrials.dfhcc.harvard.edu/trials/903 Proton Beam Radiation Therapy in Treating Young Patients Who Have Undergone Biopsy or Surgery for Medulloblastoma or Pineoblastoma RATIONALE: Specialized radiation therapy that delivers radiation directly to the area where a tumor was surgically removed may kill any remaining tumor cells and cause less damage to normal tissue. PURPOSE: This phase II trial is studying how well proton beam radiation therapy works in treating young patients who have undergone biopsy or surgery for medulloblastoma or pineoblastoma. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 2 1041 http://clinicaltrials.dfhcc.harvard.edu/trials/1041 Epothilone B in Treating Patients With CNS Metastases From Breast Cancer RATIONALE: Drugs used in chemotherapy, such as epothilone B, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well epothilone B works in treating patients with CNS metastases from breast cancer. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer 3 Breast Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/3-breast-cancer Phase 2 191 http://clinicaltrials.dfhcc.harvard.edu/trials/191 ZK219477 in Patients With Breast Cancer and Brain Metastases The purpose of this research study is to determine the effects (good and bad) of ZK219477 on participants and their cancer. ZK219477 is a chemotherapy drug that is thought to work by interfering with the ability of cancer cells to grow and divide. It is a part of a group of drugs called "epothilones" which appear to cause shrinkage of cancer in some patients with breast cancer. It is generally difficult for chemotherapy to enter the brain. However, it is believed that ZK219477 crosses into the brain. We are also studying whether an investigational MRI scan procedure may eventually help to predict which patients will benefit from ZK219477. Recruiting 3 Breast Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/3-breast-cancer 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 2 27 http://clinicaltrials.dfhcc.harvard.edu/trials/27 LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has no yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 1/Phase 2 76 http://clinicaltrials.dfhcc.harvard.edu/trials/76 Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma RATIONALE: Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving cediranib together with temozolomide and radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of cediranib to see how well it works when given together with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 1/Phase 2 218 http://clinicaltrials.dfhcc.harvard.edu/trials/218 Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors Phase I: The purpose of this research study is to determine the safety of the combination treatment of ZD6474 (Vandetanib) with the standard therapy for glioblastomas and gliosarcomas, temozolomide (Temodar) and radiation therapy. This agent is investigational for the treatment of glioblastomas. We will determine the highest dose of ZD6474 (Vandetanib) that can be given safely when combined with temozolomide (Temodar) and radiation therapy. Phase II: The purpose of this research study is to determine the efficacy of the combination treatment of ZD6474 (Vandetanib) with the standard therapy for glioblastomas and gliosarcomas, temozolomide (Temodar) and radiation therapy. This agent is investigational for the treatment of glioblastomas. All subjects participating in this research study must NOT be taking a certain type of anti-seizure medication called enzyme inducing anticonvulsant drugs. These drugs include the following medications: Dilantin, Tegretol, Phenobarbital and trileptal. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 1/Phase 2 299 http://clinicaltrials.dfhcc.harvard.edu/trials/299 Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma RATIONALE: Sorafenib, erlotinib, tipifarnib, and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib and tipifarnib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib together with erlotinib, tipifarnib, or temsirolimus may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib, tipifarnib, and temsirolimus when given together with sorafenib and to see how well they work in treating patients with recurrent glioblastoma multiforme or gliosarcoma. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 1/Phase 2 951 http://clinicaltrials.dfhcc.harvard.edu/trials/951 Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma RATIONALE: Tandutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of tandutinib and to see how well it works in treating patients with recurrent or progressive glioblastoma. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 1/Phase 2 72 http://clinicaltrials.dfhcc.harvard.edu/trials/72 Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma This study is evaluating a combination of drugs called sirolimus and vandetanib to treat glioblastoma. Sirolimus has been approved for use in patients who undergo organ transplants. Sirolimus works by suppressing the immune system so the body will not reject the transplanted organ. Vandetanib is an investigational drug and we are trying to find the highest and safest dose of vandetanib with sirolimus that can be given safely. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 1 87 http://clinicaltrials.dfhcc.harvard.edu/trials/87 Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors The purpose of this research study is to determine the safety of the combination of SOM230 and RAD001, as well as determine the highest dose of this combination that can be given to people safely. SOM230 is an investigational drug that is similar to Sandostatin LAR. Sandostatin is an approved drug for the use of treating symptoms of neuroendocrine tumors. SOM230 has shown to be effective in patients who have become resistant to Sandostatin and may also stop cancer cells from growing. RAD001 is an investigational drug that also may stop cancer cells from growing. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 1 217 http://clinicaltrials.dfhcc.harvard.edu/trials/217 Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas RATIONALE: Drugs used in chemotherapy, such as vorinostat and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may help temozolomide work better by making tumor cells more sensitive to the drug. Giving vorinostat together with temozolomide may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating patients with malignant gliomas. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 1 1172 http://clinicaltrials.dfhcc.harvard.edu/trials/1172 Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors The purpose of this research study is to find out more about the combination of RAD001 and sorafenib such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating neuroendocrine tumors. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 1 63 http://clinicaltrials.dfhcc.harvard.edu/trials/63 Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma RATIONALE: Aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving aflibercept together with radiation therapy and temozolomide may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of aflibercept when given together with radiation therapy and temozolomide in treating patients with newly diagnosed or recurrent glioblastoma multiforme, gliosarcoma, or other malignant glioma. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 1 71 http://clinicaltrials.dfhcc.harvard.edu/trials/71 Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer The purpose of this research study is to determine the safety of combining lapatinib plus radiation in patients with breast cancer that has spread to the brain. Depending upon the participants cancer, they may also have stereotactic radiosurgery (SRS). Lapatinib s a compound that may stop cancer cells from growing abnormally. It is thought that lapatinib might also make cancer cells more sensitive to radiation. This drug has been used in other research studies in women with breast cancer, and information from those other research studies suggests that lapatinib may help to shrink or stabilize breast tumors both inside the brain and outside the brain. Recruiting 3 Breast Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/3-breast-cancer 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 1 1163 http://clinicaltrials.dfhcc.harvard.edu/trials/1163 AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases From Non-Small Cell Lung Cancer In this research study the investigators are looking for the highest dose of AZD2171 that can be given safely to participants with brain metastases who are being treated with whole brain radiation. The investigators also want to see what side effects participants experience when taking AZD2171. The researchers are looking at the effect of this drug on the participants's tumor size and disease progression. This drug works by interfering with (or inhibiting) a substance called VEGF (Vascular Endothelial Growth Factor). VEGF helps tumors grow and survive by supporting the growth of the blood vessels that bring nutrients to the tumor. When the activity of VEGF is interrupted, the blood vessels around the tumor cells die. The tumors may then die because nutrients aren't getting to the tumor. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer Phase 1 149 http://clinicaltrials.dfhcc.harvard.edu/trials/149 Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma The purpose of this research study is to determine if sunitinib can get past the blood-brain barrier and into the brain tumor. Sunitinib has shown promising results in treating other cancers and works by blocking blood flow to tumors, which may prevent them from growing further. At the present time, there is no chemotherapy that can cure glioblastoma. The reason why chemotherapy is not fully effective is that many drugs cannot penetrate into brain tumors. This is due to the presence of the blood-brain barrier (BBB) which normally protects the brain from substances in the blood. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer N/A 886 http://clinicaltrials.dfhcc.harvard.edu/trials/886 Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 The purpose of this research study is to determine if ranibizumab can prevent the growth of neurofibromas. We will also be collecting extra blood and serum samples to help us learn more about NF1. Ranibizumab is a drug that affects the development of blood vessels that feed tumors. It targets a substance in the body called VEGF (Vascular Endothelial Growth Factor). VEGF helps tumors to grow and survive by supporting the growth of blood vessels that bring nutrients to the tumor. VEGF is made by cancerous tumors and also by non-cancerous tumors such as neurofibromas. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer N/A 924 http://clinicaltrials.dfhcc.harvard.edu/trials/924 MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme RATIONALE: Diagnostic procedures, such as MRI, may help in learning how well radiation therapy and chemotherapy work in killing tumor cells and allow doctors to plan better treatment. PURPOSE: This clinical trial is studying MRI scans to see how well they evaluate the effects of radiation therapy and chemotherapy in patients with newly diagnosed glioblastoma multiforme. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer N/A 1009 http://clinicaltrials.dfhcc.harvard.edu/trials/1009 Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma In this research study, we are looking to study the side effects from the use of proton radiation in treating people with low-grade gliomas that are recommended radiation treatment. We expect response of the tumors to be the same with proton radiation as compared to standard 3D conformal radiation therapy, but also expect less side effects from radiation. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer N/A 1025 http://clinicaltrials.dfhcc.harvard.edu/trials/1025 Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1 The purpose of this study is to determine if imiquimod cream can reverse the growth of neurofibromas. Imiquimod is a skin cream that works by stimulating the body's immune system to respond to tumors. Imiquimod cream is approved for use in patients with various skin lesions, including actinic keratosis, superficial basal cell carcinoma, and external genital warts. Information from these studies, as well as previous laboratory studies, suggest that imiquimod cream may help shrink neurofibromas or keep them from growing. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer N/A 1190 http://clinicaltrials.dfhcc.harvard.edu/trials/1190 Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-Cis-Retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors The purpose of this study is to: Find out how safe and effective (by monitoring the good and/or bad effects) treatment with high dose temozolomide, thiotepa and carboplatin with stem cell rescue followed by 13-cisretinoic acid has on children and adolescents with recurrent/refractory brain tumors Find out how the body uses 13-cisretinoic acid by studying the your blood levels and proteins in the blood that break down the 13-cisretinoic acid Determine how well 13-cisretinoic acid penetrates into the spinal fluid. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer 1194 http://clinicaltrials.dfhcc.harvard.edu/trials/1194 Phase II Study of PF-04948568 (CDX-110) in Patients With Glioblastoma Multiforme This study is designed to evaluate the clinical activity of CDX-110 vaccination when given with standard of care treatment (maintenance temozolomide therapy). Study treatment will be given until disease progression and patients will be followed for long-term survival information. Efficacy will be measured by the progression-free survival status at 5.5 months from the date of first dose. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer 1209 http://clinicaltrials.dfhcc.harvard.edu/trials/1209 A Study of XL765 in Combination With Temozolomide in Adults With Malignant Gliomas The purpose of this study is to determine the safety and tolerability of XL765 in combination with Temozolomide in adults with anaplastic gliomas or glioblastoma on a stable Temozolamide maintenance dose. XL765 is a new chemical entity that inhibits the kinases PI3K and mTOR. In preclinical studies, inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells, whereas inactivation of mTOR has been shown to inhibit the growth of tumor cells. Temozolomide (TMZ, Temodar®) is an orally administered alkylating agent with activity against malignant gliomas. It is approved by the Food and Drug Administration for the following indications: 1) treatment of newly diagnosed glioblastoma multiforme (GBM) patients when given concomitantly with radiotherapy and then as maintenance treatment; 2) refractory anaplastic astrocytoma (AA), ie, patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine. Temozolomide is commonly used in the treatment of other anaplastic gliomas (AG) including oligodendroglial tumors and mixed gliomas. Recruiting 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer